Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Elevate Your Wellness LLC, dba Elevated

Has Elevated received an FDA warning letter? Yes. FDA issued a warning letter dated September 9, 2025 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
September 9, 2025 (2025-09-09)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded semaglutidecompounded tirzepatideSemaglutide ODT
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website claims for compounded semaglutide and tirzepatide imply they are the same as FDA-approved GLP-1 drugs. These claims are false or misleading, making products misbranded under FDCA 502(a) and 502(bb).

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding
  • false or misleading advertising/promotion

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.